Arcutis Biotherapeutics, Inc. - Common Stock (ARQT)
CUSIP: 03969K108
Q4 2021 13F Holders as of 31 Dec 2021
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 122,541,881
- Total 13F shares
- 46,348,278
- Share change
- +33,258
- Total reported value
- $961,255,152
- Put/Call ratio
- 22%
- Price per share
- $20.74
- Number of holders
- 89
- Value change
- -$1,852,441
- Number of buys
- 47
- Number of sells
- 40
Quarterly Holders Quick Answers
What is CUSIP 03969K108?
CUSIP 03969K108 identifies ARQT - Arcutis Biotherapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03969K108:
Top shareholders of ARQT - Arcutis Biotherapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FRAZIER MANAGEMENT LLC |
13F
|
Company |
6.9%
|
8,434,232
|
$201,494,000 | — | 30 Sep 2021 | |
| FMR LLC |
13F
|
Company |
6.1%
|
7,536,265
|
$180,041,000 | — | 30 Sep 2021 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
5%
|
6,073,850
|
$145,104,000 | — | 30 Sep 2021 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.4%
|
4,195,926
|
$100,241,000 | — | 30 Sep 2021 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
3.2%
|
3,979,292
|
$95,065,000 | — | 30 Sep 2021 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.6%
|
1,992,107
|
$47,591,000 | — | 30 Sep 2021 | |
| Polar Capital Holdings Plc |
13F
|
Company |
1.3%
|
1,548,901
|
$37,003,000 | — | 30 Sep 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.2%
|
1,492,207
|
$35,648,000 | — | 30 Sep 2021 | |
| STATE STREET CORP |
13F
|
Company |
0.85%
|
1,039,213
|
$24,827,000 | — | 30 Sep 2021 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.66%
|
813,694
|
$19,439,000 | — | 30 Sep 2021 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.63%
|
773,214
|
$18,472,000 | — | 30 Sep 2021 | |
| SECTORAL ASSET MANAGEMENT INC |
13F
|
Company |
0.62%
|
758,763
|
$18,127,000 | — | 30 Sep 2021 | |
| Omega Fund Management, LLC |
13F
|
Company |
0.51%
|
623,836
|
$14,903,000 | — | 30 Sep 2021 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.47%
|
575,208
|
$13,741,000 | — | 30 Sep 2021 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
0.46%
|
569,041
|
$13,594,000 | — | 30 Sep 2021 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.4%
|
488,855
|
$11,678,000 | — | 30 Sep 2021 | |
| Vivo Capital, LLC |
13F
|
Company |
0.35%
|
433,585
|
$10,358,000 | — | 30 Sep 2021 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.32%
|
389,938
|
$9,316,000 | — | 30 Sep 2021 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.31%
|
376,074
|
$8,985,000 | — | 30 Sep 2021 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.3%
|
362,035
|
$8,655,000 | — | 30 Sep 2021 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.22%
|
270,519
|
$6,463,000 | — | 30 Sep 2021 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.22%
|
265,932
|
$6,353,000 | — | 30 Sep 2021 | |
| AXA S.A. |
13F
|
Company |
0.21%
|
259,084
|
$6,190,000 | — | 30 Sep 2021 | |
| Altium Capital Management LLC |
13F
|
Company |
0.21%
|
255,000
|
$6,092,000 | — | 30 Sep 2021 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.18%
|
219,392
|
$4,973,000 | — | 30 Sep 2021 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.16%
|
195,837
|
$4,679,000 | — | 30 Sep 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0.12%
|
143,731
|
$3,434,000 | — | 30 Sep 2021 | |
| Tekla Capital Management LLC |
13F
|
Company |
0.11%
|
131,633
|
$3,145,000 | — | 30 Sep 2021 | |
| Neuberger Berman Group LLC |
13F
|
Company |
0.1%
|
122,087
|
$2,916,000 | — | 30 Sep 2021 | |
| PURA VIDA INVESTMENTS, LLC |
13F
|
Company |
0.09%
|
112,324
|
$2,683,000 | — | 30 Sep 2021 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
95,064
|
$2,271,000 | — | 30 Sep 2021 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.06%
|
79,395
|
$1,894,000 | — | 30 Sep 2021 | |
| ALPS ADVISORS INC |
13F
|
Company |
0.05%
|
61,578
|
$1,471,000 | — | 30 Sep 2021 | |
| NORGES BANK |
13F
|
Company |
0.05%
|
61,116
|
$1,460,000 | — | 30 Sep 2021 | |
| Swiss National Bank |
13F
|
Company |
0.05%
|
55,200
|
$1,319,000 | — | 30 Sep 2021 | |
| HAMILTON LANE ADVISORS LLC |
13F
|
Company |
0.04%
|
52,347
|
$1,251,000 | — | 30 Sep 2021 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.03%
|
40,627
|
$971,000 | — | 30 Sep 2021 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.03%
|
35,584
|
$850,000 | — | 30 Sep 2021 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.03%
|
35,513
|
$848,000 | — | 30 Sep 2021 | |
| AlphaCentric Advisors LLC |
13F
|
Company |
0.03%
|
35,500
|
$848,000 | — | 30 Sep 2021 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.02%
|
30,618
|
$731,000 | — | 30 Sep 2021 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.02%
|
30,596
|
$731,000 | — | 30 Sep 2021 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.02%
|
30,510
|
$729,000 | — | 30 Sep 2021 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.02%
|
30,223
|
$722,000 | — | 30 Sep 2021 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
30,155
|
$720,000 | — | 30 Sep 2021 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.02%
|
29,972
|
$716,031 | — | 30 Sep 2021 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.02%
|
27,970
|
$668,000 | — | 30 Sep 2021 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.02%
|
27,700
|
$662,000 | — | 30 Sep 2021 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.02%
|
25,300
|
$604,000 | — | 30 Sep 2021 | |
| CITIGROUP INC |
13F
|
Company |
0.02%
|
24,936
|
$596,000 | — | 30 Sep 2021 |
Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q4 2021
As of 31 Dec 2021,
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) was held by
89 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,348,278 shares.
The largest 10 holders included
FRAZIER MANAGEMENT LLC, FMR LLC, ORBIMED ADVISORS LLC, BlackRock Inc., Bain Capital Life Sciences Investors, LLC, Point72 Asset Management, L.P., Polar Capital Holdings Plc, VANGUARD GROUP INC, STATE STREET CORP, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
89
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2021 vs Q3 2021 Across Filers
Q3 2021 holders
103
Q4 2021 holders
89
Holder diff
-14
| Investor | Q3 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q3 2021 Value $ | Q4 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.